DRRX News

DURECT Corporation Reports Second Quarter 2025 Financial Results and Provides Update on Proposed Acquisition by Bausch Health

Bausch Health will pay $1.75 per share plus up to $350 million in aggregate sales milestones Transaction expected to close in the third quarter of 2025 CUPERTINO, Calif., Aug. 12, 2025 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the second...

August 12, 2025Mergers

Durect Q1 EPS $(0.13) Misses $(0.12) Estimate, Sales $321.00K Beat $291.67K Estimate

DRRX

May 13, 2025

HC Wainwright & Co. Reiterates Neutral on Durectto Neutral

DRRX

March 27, 2025

Durect Q4 2024 GAAP EPS $0.24 Beats $(0.02) Estimate, Sales $500.000K Miss $6.907M Estimate

DRRX

March 26, 2025

HC Wainwright & Co. Reiterates Neutral on Durect

DRRX

November 14, 2024

HC Wainwright & Co. Reiterates Neutral on Durect

DRRX

May 22, 2024

Watching DURECT; Traders Circulate Unconfirmed Analyst Comments Suggesting A $5 PT on The Stock After FDA Feedback

DRRX

May 21, 2024

DURECT Corporation Receives FDA Breakthrough Therapy Designation For Larsucosterol In Alcohol-Associated Hepatitis

DRRX

May 21, 2024

Durect Q1 Net Loss $10.8M, Sales $1.90M Miss $2.28M Estimate

DRRX

May 4, 2022

Earnings Outlook For Durect

DRRX

Durect (NASDAQ:DRRX) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that Durect will report an earnings per share (EPS) of $-0.05.

May 3, 2022